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Abstract
Background: Accumulating evidence suggests that thiazolidinediones (TZDs) may exert protective effects in atrial
fibrillation (AF). The present meta-analysis investigated the association between TZD use and the incidence of AF in
diabetic patients.
Methods: Electronic databases were searched until December 2016. Of the 346 initially identified records, 3
randomized clinical trials (RCTs) and 4 observational studies with 130,854 diabetic patients were included in the
final analysis.
Results: Pooled analysis of the included studies demonstrated that patients treated with TZDs had approximately
30% lower risk of developing AF compared to controls [odds ratio (OR): 0.73, 95% confidence interval (CI): 0.62 to
0.87, p = 0.0003]. This association was consistently observed for both new onset AF (OR =0.77, p = 0.002) and
recurrent AF (OR =0.41, p = 0.002), pioglitazone use (OR =0.56, p = 0.04) but not rosiglitazone use (OR =0.78,
p = 0.12). The association between TZD use and AF incidence was not significant in the pooled analysis of three
RCTs (OR =0.77, 95% CI = 0.53–1.12, p = 0.17), but was significantly in the pooled analysis of the four observational
studies (OR =0.71, p = 0.0003).
Conclusions: This meta-analysis suggests that TZDs may confer protection against AF in the setting of diabetes
mellitus (DM). This class of drugs can be used as upstream therapy for DM patients to prevent the development of AF.
Further large-scale RCTs are needed to determine whether TZDs use could prevent AF in the setting of DM.
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Background
Atrial fibrillation (AF) is the most prevalent arrhythmia
observed in clinical practice, and is associated with sig-
nificant morbidity and mortality in the popuation. The
burden of AF increases over time mainly due to an aging
population and to the increasing prevalence of cardio-
vascular comorbidities. However, strategies to predict
and prevent AF are not fully effective [1]. Diabetes melli-
tus (DM) is one of the strongest independent risk factors
for AF incidence, conferring an approximate 40% higher
risk of subsequent AF development [2, 3]. It also predicts
the recurrence of AF following a successful direct current
cardioversion [4]. Moreover, DM increases the risk of de-
veloping stroke, heart failure, and cardiovascular death in
patients with AF [5]. Although the exact pathophysio-
logical mechanisms linking DM and AF remain incom-
pletely elucidated, an increasing body of evidence suggests
that inflammation and oxidative stress may play an im-
portant role [6–8].
Thiazolidinediones (TZDs), a class of peroxisome
proliferator-activated receptor-γ (PPAR-γ) agonists, are
among the most potent insulin-sensitizing drugs [9].
Apart from their anti-diabetic activity, TZDs display sev-
eral pleiotropic effects including anti-inflammatory and
antioxidant actions that may have potential benefits for
AF prevention [10, 11]. However, inconsistent results
have been reported regarding TZDs use and AF incidence
[12–18]. In light of such conflicting data, we performed a
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comprehensive meta-analysis to evaluate the present evi-
dence and investigate whether the use of TZDs confers
benefits in preventing AF.
Methods
This systematic review was conducted according to the
Quality of Reports of Meta-Analyses of Randomized
Controlled Trials (QUOROM) recommendations [19]
and the guidelines of the Meta-analysis of Observational
Studies in Epidemiology Group (MOOSE) [20].
Inclusion criteria
The studies considered for this meta-analysis were either
randomized clinical trials (RCTs) or observational stud-
ies that investigated the potential effects of TZDs on AF.
The inclusion criteria were as follows: RCTs: 1) random-
ized controlled human trials with a parallel design; 2)
comparison of TZDs with control; 3) collecting data on
new or recurrent AF during follow-up. Observational
Studies: 1) comparison of TZDs with control; 2) evaluat-
ing new or recurrent AF as an outcome. In the studies
of interventions with TZDs no limit in the length of
follow-up period was set due to the paucity of relevant
studies.
Search strategies
A systematic literature search was performed by two in-
vestigators (Z. Z. and X. Z.) using the online databases
of PubMed and Embase to identify relevant studies pub-
lished before December 2016. The following key terms
were used: “thiazolidinediones”, “pioglitazone”, “rosiglita-
zone”, “troglitazone”, and “atrial fibrillation”. Both inves-
tigators independently evaluated the search results and
identified potential studies for further assessment. Dis-
agreements were resolved by a third reviewer (T. L.).
Quality assessment and data extraction
As quality scoring in meta-analyses of RCTs and obser-
vational studies is controversial, several key points of
study quality were assessed according to a critical review
checklist of Wynn et al. [21]. The key points of this
checklist and quality assessments of included studies are
listed in Table 1.
Two investigators (Z. Z. and X. Z.) independently ex-
tracted the relevant data using a pre-defined spread-
sheets. The extracted data elements of the meta-analysis
included information on the inclusion criteria, publica-
tion details, study design, follow-up duration, daily dos-
age of TZDs, definition of AF, methods of AF detection,
baseline patient characteristics, the variables of multi-
variate model used in observational studies and results.
Disagreements were resolved through discussion or con-
sensus with a third reviewer (T. L.).
Statistical analysis
Results of the AF outcome are expressed as odds ratio
(OR) with 95% confidence interval (CI) for each study
using generic inverse-variance method. The hazard ratio
value using multivariate Cox proportional hazards model
in the primary study was directly considered as OR [22].
Raw event numbers were extracted from the RCTs and
adjusted effect estimates from the observational studies
to calculate the overall effects. Statistical heterogeneity
was assessed by the χ2 test and quantified by using the I2
statistic. An I2 > 50% is indicative of at least moderate
heterogeneity [23]. A random-effects model was used.
Subgroup analyses regarding AF subtypes (new onset AF
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or recurrent AF), different TZDs (solely pioglitazone or
solely rosiglitazone), study designs (RCTs or observa-
tional studies), and different follow-up duration (>5 years
or ≤5 years) were additionally performed. Sensitivity
analysis was done by removing one study at a time and
checking the consequent effects on the effect estimate.
Publication bias was evaluated using a funnel plot. Two-
tailed p values of <0.05 were considered statistically sig-
nificant. The statistical analysis was performed using the
Review Manager (RevMan, version 5.3, Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
2014).
Results
A total of 346 records were identified initially through
our literature search strategy. After careful assessment,
seven studies (three RCTs [12, 14, 17] and four observa-
tional studies [13, 15, 16, 18]) comprising 130,854 dia-
betic patients (11,781 in the treatment and 119,073 in
the control group) were included in the final meta-
analysis (Fig. 1).
Three studies [12, 15, 17] examined the relationship
between pioglitazone use and AF, while two other [14, 16]
studied rosiglitazone use. The remaining two studies [13,
18] reported data regarding the use of pioglitazone, rosigli-
tazone and troglitazone. The characteristics of each study
are listed in Table 2, and the patients’ characteristics in
each study are shown in Table 3.
Of the seven studies, four [15–18] studies showed that
TZDs use attenuated either the risk of new-onset or re-
current AF, whereas the other three [12–14] studies did
not indicate a statistically significant difference. Overall,
the pooled analysis of the seven included studies sug-
gested that patients treated with TZDs have nearly 30%
lower risk of AF compared with controls (OR =0.73, 95%
CI = 0.62–0.87, p = 0.0003; Fig. 2). No significant het-
erogeneity between the individual studies was observed
(P = 0.36, I2 = 9%).
Subgroup analyses according to AF types, different
TZDs, follow-up duration, and study designs were sub-
sequently performed (Fig. 2, Table 4). TZDs use was as-
sociated with a decrease in the risk of both new-onset
[12, 14, 16, 18] (OR =0.77, 95% CI = 0.65–0.91,
p = 0.002) and recurrent AF [13, 15, 17] (OR =0.41, 95%
CI = 0.24–0.72, 0.002) without any heterogeneity across
the studies. Regarding different TZDs, pioglitazone use
[12, 15, 17] (OR =0.56, 95% CI = 0.32–0.98, p = 0.04;
I2 = 54%) was associated with a lower risk of AF incidence,
whereas rosiglitazone use [14, 16] was not significantly as-
sociated with a decreasing AF incidence (OR =0.78, 95%
CI = 0.57–1.07, p = 0.12; I2 = 34%). Regarding the sub-
group analysis on different follow-up duration, there was
no significant difference between the 3 studies [14, 16, 18]
with a follow-up duration >5 years (OR =0.76, 95%
CI = 0.63–0.91, p = 0.002; I2 = 0%) and the 4 studies [12,
13, 15, 17] with a follow-up duration ≤5 years (OR =0.62,
95% CI = 0.41–0.94, p = 0.02; I2 = 34%). Finally, the
pooled analysis of the 4 [13, 15, 16, 18] observational stud-
ies showed a strong association between TZDs use and
risk reduction of AF (OR =0.71, 95% CI = 0.59–0.85,
p = 0.0003; I2 = 0%), whereas the pooled analysis of the
three RCTs showed a non-statistically significant 23% re-
duction in the odds of developing AF (OR =0.77, 95%
CI = 0.53–1.12, p = 0.10; I2 = 40%).
Besides, due to different pathophysiologic mechanisms
of AF, a sensitivity analysis was performed by removing
the studies evaluated post-operation AF [13] and post-
AF [15] ablation recurrences, no significant differences
were found in the heterogeneity (P = 0.44; I2 = 0%)
among the remaining five studies [12, 14, 16–18], and
the overall outcome remained the same (OR =0.75, 95%
CI = 0.64–0.88, p = 0.0003).
Discussion
The main findings of this comprehensive meta-analysis
on 130,854 diabetic patients are the following: i. TZDs
may confer protection against AF incidence; ii. the bene-
ficial effects of TZDs were consistently observed in both
new onset and recurrent AF; iii. Pioglitazone use was as-
sociated with a statistically reduced risk of incident AF,
whereas rosiglitazone use showed no statistically signifi-
cant difference; and iv. the protective effects of TZDs
Fig. 1 Flow diagram of the study selection process
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were only observed in the pooled analysis of the obser-
vational studies rather than the RCTs.
The PROactive [12] and RECORD [14] RCTs showed
that pioglitazone or rosiglitazone use does not provide
any benefit in preventing AF incidence among high-risk
patients with type 2 DM. However, in these two RCTs,
AF was reported as an adverse event rather than a prede-
fined endpoint. Furthermore, these trials displayed a very
low AF incidence in both intervention and control groups
(1.5–2%), and thus AF detection may be underpowered.
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CABG coronary artery bypass graft, TZDs thiazolidinediones, LAD left atrial diameter, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor
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Moreover, in the present meta-analysis, we observed
that pioglitazone use was associated with beneficial ef-
fects on AF prevention compared with rosiglitazone use.
Similarly, previous study suggested that pioglitazone has
a beneficial effect on cardiovascular disease, whereas
rosiglitazone seemed to increase cardiovascular risk [24].
By assembling a diabetic cohort of older than 65 years,
Winkelmayer et al. [25] demonstrated greater risk of
mortality and congestive heart failure among patients
who initiated therapy with rosiglitazone compared with
pioglitazone, however, there were no differences in their
incidences of myocardial infarction or stroke. Previous
data [26] also showed similar effects on glycemic control
between pioglitazone and rosiglitazone, as well as on
other parameters such as C-reactive protein (CRP), plas-
minogen activator inhibitor-1 and indices of insulin se-
cretion and sensitivity. However, pioglitazone treatment
was associated with greater beneficial changes on plasma
lipids than rosiglitazone treatment [26], which may
partly explain the advantage of pioglitazone in reducing
AF incidence.
Recently, the IRIS trial [27] demonstrated that pioglit-
azone can prevent fatal or nonfatal stroke or myocardial
infarction among patients who have insulin resistance
along with cerebrovascular disease. However, the under-
lying mechanism for these beneficial effects of pioglita-
zone remains incompletely elucidated. AF is a known
risk factor of morbidity and mortality by predisposing to
strokes and acute coronary syndrome [28]. Thus, it is
possible to postulate that pioglitazone reduces the stroke
or MI events partly through the reduction of AF burden.
Accumulating evidence supports the role of inflamma-
tion and immune response activation in the genesis and
perpetuation of AF in different clinical settings, includ-
ing cardiac surgery, electrical cardioversion and catheter
ablation [29]. Oxidative stress has been suggested to play
Table 4 Subgroup analyses of the association between TZDs and AF
Subgroup Study Number of
studies
Heterogeneity Meta-analysis
I2 P-Value OR 95% CI p-Value
AF types New-onset AF 4 0% 0.64 0.77 0.65–0.91 0.002
Recurrent AF 2 0% 0.54 0.41 0.24–0.72 0.002
TZDs Solely pioglitazone 3 54% 0.11 0.56 0.32–0.98 0.04
Solely rosiglitazone 2 34% 0.22 0.78 0.57–1.07 0.12
Follow-up duration ≤ 5 years 4 34% 0.21 0.62 0.41–0.94 0.02
> 5 years 3 0 0.47 0.76 0.63–0.91 0.002
Study design RCTs 3 40% 0.10 0.77 0.53–1.12 0.17
Observational studies 4 0% 0.41 0.71 0.59–0.85 0.0003
Abbreviations: TZDs thiazolidinediones, AF atrial fibrillation, RCTs randomized controlled trials, OR odds ratio, CI confidence interval
Fig. 2 Forest plot showing the association association between thiazolidinediones (TZDs) and atrial fibrillation (AF)
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an important role in AF incidence [30]. Numerous studies
have demonstrated that TZDs may attenuate inflamma-
tion and oxidative stress as well as atrial electrophysio-
logical and structural remodeling in different animal
models.
In a ventricular tachypacing-induced CHF rabbit model,
Shimano et al. [31] showed that pioglitazone prevents atrial
structural remodeling and inhibits AF promotion. Also,
similarly to candesartan, pioglitazone suppresses trans-
forming growth factor-β1 (TGF-β1) and tumor necrosis
factor-α (TNF-α) expression in atrial tissue, molecules that
are inflammatory mediators related to fibrosis-mediated
AF incidence [29]. More recently, Kume et al. [32]
suggested that pioglitazone effectively attenuates in-
flammatory profibrotic signals and vulnerability to AF
in a pressure overload AF rat model, possibly via its
suppression in monocyte chemoattractant protein (MCP-1)
expression. PPAR-γ agonists have been shown to attenuate
Angiotensin II (Ang II) -induced atrial electrical and struc-
tural remodeling in cellular models [33]. These effects are
mediated by prevention of ICa-L remodeling by inhibiting
CAMP responsive element binding protein (CREB) phos-
phorylation, as well as by suppression of connective tissue
growth factor (CTGF) expression and cell proliferation via
inhibiting TGF-β1/Smad2/3 and TGF-β1/tumor necrosis
factor receptor associated factor 6 (TRAF6)/TGF-β-associ-
ated kinase 1 (TAK1) signaling pathways. In addition, Pio-
glitazone exhibits beneficial effects on Ang II-induced
potassium channel remodeling [34]. More recently, Chen et
al. [35] further indicated that pioglitazone inhibits Ang II-
induced atrial fibroblasts proliferation through nuclear
factor-κB (NF-κB)/TGF-β1/Toll/IL-1 receptor domain-
containing adaptor inducing IFN-β (TRIF)/TRAF6 signal-
ing pathway. Additionally, Xu et al. [36] suggested that
pioglitazone prevents age-related arrhythmogenic atrial
remodeling and AF incidence by improving heat shock
protein (HSP) 70 expression and antioxidant capacity,
and by inhibiting the mitochondrial apoptotic signaling
pathway. In an alloxan-induced diabetic rabbit model,
we have shown that rosiglitazone attenuates arrhyth-
mogenic atrial structural remodeling and AF incidence
via anti-inflammatory and antioxidant effects [37]. In
keeping with these findings, the IRIS trial found lower
CRP levels in the pioglitazone group than in the placebo
group. Indeed, increased CRP levels have been associated
with greater risk of AF [38].
Finally, the treatment of hyperglycemia may have fa-
vorable effects on AF burden. In other words, treatment
of DM may ameliorate atrial remodeling [7]. Haemoglo-
bin A1c levels have been associated with the occurrence
and recurrence of AF [7, 39, 40], and therefore TZDs
may exert their favorable effects through HbA1c level
reduction.
Study limitations
The present meta-analysis has potential limitations.
Firstly, due to the small number of included studies we
analyzed observational studies and RCTs together while
2 included RCTs reported AF as an adverse event rather
than a predefined endpoint, and the favorable effects of
TZDs use on preventing AF incidence were predomin-
ately driven by observational studies, whereas data from
the 2 RCTs were unable to draw unanimous conclusion.
Secondly, information regarding methods of AF detec-
tion, cardiac substrate, ejection fraction and atrial vol-
ume were not fully presented in our analysis due to the
lack of relative data. Thirdly, the heterogeneous types of
patient populations (ranging from uncomplicated type 2
Fig. 3 Funnel plot of meta-analysis
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diabetics to post-CABG or post-AF ablation patients)
may indicate latent bias in this meta-analysis. Fourthly,
“gray” literature (primarily conference abstracts/presen-
tations, ongoing studies, communication with investiga-
tors) was not searched. Finally, the results of the funnel
plot suggested that publication bias may be present, al-
though the small number of studies made this somewhat
difficult to interpret (Fig. 3).
Conclusions
In summary, this meta-analysis suggests that TZDs may
be effective in AF prevention in the setting of DM.
Therefore, TZDs may be considered as the treatment of
choice in diabetic patient with high risk features for AF
incidence. Since the overall conclusion was mainly
drawn from the observational studies, further large-scale
prospective RCTs that assessed AF as a predefined out-
come are needed to determine whether TZDs use could
prevent AF in the setting of DM.
Abbreviations
AF: Atrial fibrillation; CHF: Congestive heart failure; CI: Confidence interval;
CRP: C-reactive protein; DM: Diabetes mellitus; OR: Odds ratio; PPAR-γ: Peroxisome
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